Cellular oncology (Dordrecht, Netherlands) · 2026
Tumor lymph node metastasis chip reveals that the NECTIN3-TIGIT axis promotes melanoma metastasis by enhancing treg cell function and inducing CD8+ T cell exhaustion.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Song Cuihao, Zhu Wenwei, Li Yaolin, Ji Yuhan, Liu Xiaoling, Zhang Yingjie, Zhang Xiaoning, Wei Fangfang, Yang Hexi, Liang Likeng, Huang Shuyan, Li Chengxin, Zhou Yong
Аннотация
PURPOSE: To investigate the role and molecular mechanism of the NECTIN3-TIGIT axis in melanoma lymph node metastasis.
METHODS: Single-cell RNA sequencing was performed on human primary melanoma and lymph node metastatic tissues. A tumor lymph node metastasis-on-a-chip model incorporating vascular, lymphatic, and dual-tumor modules was constructed, along with in vitro coculture systems using CD8+ T cells and regulatory T cells. Functional blockade was achieved via NECTIN3 knockdown, TIGIT inhibitor (Tiragolumab), and combined antiPD1 therapy.
RESULTS: The NECTIN3-TIGIT axis was identified as a core immune ligand-receptor pair in the highmetastasis subgroup, associated with increased regulatory T cell infiltration and CD8+ T cell exhaustion. Both NECTIN3 and TIGIT expression were significantly elevated in metastatic lesions and correlated with reduced overall survival. The chip model recapitulated melanoma lymphatic migration and confirmed the immunosuppressive microenvironment. Mechanistically, the NECTIN3-TIGIT axis induced CD8+ T cell exhaustion via the SHIP-1/TRAF6 pathway and promoted regulatory T cell activation by inhibiting AKT/mTORC1 signaling. NECTIN3 knockdown or Tiragolumab treatment suppressed tumor lymphatic migration, while combined antiPD1 and Tiragolumab most effectively reversed T cell exhaustion, impaired regulatory T cell function, and reduced metastasis.
CONCLUSION: The NECTIN3-TIGIT axis promotes melanoma lymph node metastasis by remodeling the immunosuppressive microenvironment. Combined blockade of NECTIN3-TIGIT and PD1 pathways represents a promising therapeutic strategy.
METHODS: Single-cell RNA sequencing was performed on human primary melanoma and lymph node metastatic tissues. A tumor lymph node metastasis-on-a-chip model incorporating vascular, lymphatic, and dual-tumor modules was constructed, along with in vitro coculture systems using CD8+ T cells and regulatory T cells. Functional blockade was achieved via NECTIN3 knockdown, TIGIT inhibitor (Tiragolumab), and combined antiPD1 therapy.
RESULTS: The NECTIN3-TIGIT axis was identified as a core immune ligand-receptor pair in the highmetastasis subgroup, associated with increased regulatory T cell infiltration and CD8+ T cell exhaustion. Both NECTIN3 and TIGIT expression were significantly elevated in metastatic lesions and correlated with reduced overall survival. The chip model recapitulated melanoma lymphatic migration and confirmed the immunosuppressive microenvironment. Mechanistically, the NECTIN3-TIGIT axis induced CD8+ T cell exhaustion via the SHIP-1/TRAF6 pathway and promoted regulatory T cell activation by inhibiting AKT/mTORC1 signaling. NECTIN3 knockdown or Tiragolumab treatment suppressed tumor lymphatic migration, while combined antiPD1 and Tiragolumab most effectively reversed T cell exhaustion, impaired regulatory T cell function, and reduced metastasis.
CONCLUSION: The NECTIN3-TIGIT axis promotes melanoma lymph node metastasis by remodeling the immunosuppressive microenvironment. Combined blockade of NECTIN3-TIGIT and PD1 pathways represents a promising therapeutic strategy.